Rothschild & Co.'s Five Arrows Acquires Rimes: A Strategic MoveRothschild & Co.'s alternative assets unit, Five Arrows, recently made a strategic acquisition by purchasing Rimes from Swedish investment firm EQT. Rimes, a leading provider of enterprise data management and investment intelligence solutions, has been a significant player in the investment industry, empowering asset managers to efficiently handle market data.
The deal marks a significant milestone in Rimes' journey, which has been bolstered by EQT's support since 2020. Under EQT's ownership, Rimes experienced notable growth, expanding its technology offerings and acquiring Matrix IDM, an Australian investment data management platform. Additionally, Rimes ventured into AI with the establishment of a dedicated product division last year.
Five Arrows' decision to acquire Rimes underscores its commitment to the alternative assets space. With global assets under management exceeding €26 billion, Five Arrows is well-positioned to leverage its long-term fund FALT and principal investments division FAPI to facilitate the acquisition. The transaction, expected to close in the coming months pending regulatory approval, holds promise for both parties.
Brad Hunt, CEO of Rimes, expressed optimism about the acquisition, emphasizing its potential to propel Rimes' growth trajectory. Meanwhile, FAPI partners Vivek Kumar and Sacha Oshry highlighted Five Arrows' intention to unlock new avenues of growth for Rimes.
As the transaction unfolds, industry observers eagerly anticipate how Five Arrows' strategic vision will shape Rimes' future. The move underscores the evolving landscape of data management and investment intelligence, signaling potential shifts in the competitive dynamics within the sector.
In conclusion, Five Arrows' acquisition of Rimes marks a pivotal moment for both companies, poised to catalyze growth and innovation in the ever-evolving realm of enterprise data management and investment solutions.
Acquisition
Merck to Acquire Harpoon Therapeutics in $680M DealNavigating the Oncology Frontier with Harpoon Therapeutics Acquisition
In a significant strategic move, pharmaceutical giant Merck & Co. ( NYSE:MRK ) has announced its plans to acquire cancer drugmaker Harpoon Therapeutics Inc. ( NASDAQ:HARP ) in a transformative deal valued at $680 million. The move aims to solidify Merck's leadership position in the highly lucrative oncology space, diversifying its portfolio and positioning itself for sustained growth in the face of potential challenges for its flagship cancer immunotherapy, Keytruda.
The Deal Overview:
Merck's acquisition of Harpoon Therapeutics involves a payment of $23 per share, more than double Harpoon's last closing share price, signaling Merck's strong commitment to the strategic partnership. The deal is currently pending, awaiting approval from Harpoon shareholders, with the expected closure in the first half of 2024.
Keytruda and Beyond:
Merck's pursuit of Harpoon Therapeutics aligns with its broader strategy of seeking new sources of growth. With Keytruda generating a substantial $20.9 billion in 2022, Merck recognizes the importance of expanding its pipeline to maintain a competitive edge. Harpoon's promising early-stage trials and T-cell engager assets present Merck with an opportunity to diversify its oncology offerings and explore new avenues of therapeutic innovation.
Analyst Insights:
Merck's acquisition of Harpoon is a strategic and value-driven move. The early but promising data from Harpoon's T-cell engager assets, coupled with investor interest in similar technologies, positions Merck for potential growth in the oncology market.
Building a Robust Portfolio:
Merck's proactive approach to portfolio expansion is evident in its recent deals, including the acquisition of Daiichi Sankyo Co.'s experimental cancer drugs and the purchase of autoimmune drugmaker Prometheus. These moves showcase Merck's commitment to staying at the forefront of medical innovation and bolstering its position in key therapeutic areas.
Investor Sentiment and Momentum:
As evidenced by the stock's current trading position near the top of its 52-week range and above its 200-day simple moving average, investor sentiment towards Merck is positive.
Conclusion:
Merck's acquisition of Harpoon Therapeutics marks a pivotal moment in the pharmaceutical landscape, where innovation and strategic partnerships are crucial for sustained growth. By expanding its oncology portfolio with cutting-edge technologies, Merck positions itself as a leader in the fight against cancer, ensuring a robust pipeline and securing its role as a key player in the evolving healthcare landscape. As the deal progresses towards closure, investors and industry observers will keenly watch Merck's journey into a new era of therapeutic possibilities.
Grindrod $GRIN - Acquisition Target at a very very cheap price. NASDAQ:GRIN
Taylor Maritime Investments (TMI) closed its offer to acquire all of the issued ordinary shares in Grindrod Shipping for HKEX:26 back in October 22. NASDAQ:GRIN has since sold off sharply following concerns of imminent de-listing by TMI.
However,
TMI does not meet the compulsory acquisition threshold of at least 90% for delisting of GRIN from the JSE.
I wouldn't be surprised if NASDAQ:GRIN is the target of future buyouts from larger dry bulk shipping companies which recognise it's strong fundamentals and growth prospects.
My DCF model of NASDAQ:GRIN supports my opinion that current stock price April 2023 is very very cheap.
An opportunity to make some serious gains for the patient investor.
How do you feel?If you check at least 3/5 on the below we might be in the right place.
1. Depressed
2. Tired
3. Stressed
4. Scared
5. Out of money to buy more
I do not know about you but I have been through all of the above over the last 12 months! I made tons of mistakes no doubt about that! BUT i wIll not make the biggest one, panic sell at the bottom or in the first rally!
Some things to consider when you try to draw the picture of the next 6-12months
1. Advertising Costs or User Acquisition Costs ⬇ + NPS ⬆ ( What's doing Meow Meow on the roof???)
2. Shipping Costs + Shipping time ⬇
3. West Disposable Income ⬇
Why is Peter Selling? well, for a buyout to take place at least >50% of shareholders must agree! Now retail holds 39% + the previous 10% of Peter before starting selling makes 49%! you understand how dangerous that was for the Funds that they wanted to take over right? Probably the price is already set! nobody else besides peter is selling here! Now have a look here:
Vijay's Contract
"Restricted Stock Units. Subject to the approval of the Company’s Board of Directors or its Compensation Committee, you will be granted
an award of Restricted Stock Units (“RSUs”) for that number of shares of the Company’s Common Stock equal to $12,000,000 divided by
the average closing price of a share of the Company’s Common Stock as reported on Nasdaq during the full calendar month prior to your
Start Date, rounded down to the nearest whole share
+
"Stock Options. Subject to the approval of the Company’s Board of Directors or its Compensation Committee, you will be granted an
option to purchase that number of shares of the Company’s Class A Common Stock equal to $16,800,000 divided by the average closing
price of a share of the Company’s Common Stock as reported on Nasdaq during the full calendar month prior to your Start Date, rounded
down to the nearest whole share (the “Option”)"
The average closing price prior to the Start Date meaning Dec 21 was around $3.2 giving to Vijay the option in case he would stay with the company to hold around 9m shares or 1.3%.
So Peter's 10% + Vijay 1.3% + Retail 39% or more at the time since many got liquidated gives us >50%, if one of the funds holding 3-4% could be on their side the acquisition would be even harder to take place. Imo this is an ordered acquisition and Retail will pay for it! What a beautiful game!
Based on 670m shares float here are the % based on (simplywallst.com data and fintle.io)
Holders >1%
1. Vanguard together with its passive funds holds 84,819,961 or 12.65%
2. Blackrock together with its passive funds holds 37,909,425 or 5.65% + iShares (owned by Blackrock) 20,564,283 or 3.069%
3. Formation8 Partners 42,192,476 or 6.29%
4. DST Global 38,301,392 or 5.71%
5. GGV Capital, LLC 25,707,499 or 3,83%
6. General Atlantic Llc 16,888,478 or 2.52%
7. Maple Rock Capital Partners Inc. 13,519,000 or 2.01% +5m call option + potential 0.74%
8. State Street Corp 13,349,046 or 1.99%
9. Geode Capital Management, Llc 8,442,463 or 1.26%
10. Comprehensive Financial Management LLC 8,406,736 or 1.25%
11. Renaissance Technologies Llc 8,264,800 or 1.23%
All of the above players hold together 47.45%! Peter already sold 3.63% and probably going for >5%, when we learn who bought in i think the price would not be where it is now!
From the 2021 Annual Report
"In addition, in July 2017, FTSE Russell and Standard & Poor’s announced that they would cease to allow most
newly public companies utilizing dual or multi-class capital structures to be included in their indices. Affected indices
include the Russell 2000 and the S&P 500, S&P MidCap 400, and S&P SmallCap 600, which together make up the S&P
Composite 1500. Under the announced policies, our multi-class capital structure would make us ineligible for inclusion in
any of these indices, and as a result, mutual funds, exchange-traded funds, and other investment vehicles that attempt to
passively track these indices will not be investing in our stock."
IMO Peter's conversion from B to A opened the door for the acquisition ! Since they will scoop everything from their passive funds!
What's the price????
If the deal is done and you are the SMART MONEY wouldn't you like to purchase all the stock available??? I mean look at that depressed 39% that sits there! IMO 2 paths are possible depending on how the markets will do over the next 6-12months
1. If markets do well there will be an explosive rally to $3-5 towards the EoY, I bet most of you will take your money and leave at that point, the volatility (shaking) is going to be insane! RSI constantly overbought on divergence the opposite of what's happening now!
2. If markets do bad then 0.90-0.70 will do. I think a big % of retail will give up on new lows or on the first 100-300% rally.
Now IF and i say IF there is a buyout what would be the price? I would like to think of a price higher than the institution's average. Wish right now has no major shareholder (Peter is gone) I think VC's will likely dictate the price.
My guess would be something around 4-6x FY23 sales if markets go well! That should be in the range of 4-6b maybe a little higher depending on how sales would look in 23. That translates to a price of more or less $7-9 or Inside the GAP!!!
*Peter's Thiel Fund sold all of it's shares on the WSB frenzy for an average of $12 i think in the best best best case scenario that's the ceiling!
Do your own research and do not listen and trust nobody! In the end, we are all alone in this game!
Keep calm WGMI!
CFVI Long, It could rumblePossible WSB play if network effects of Andrew Tate could influence Zoomer capital to buy the stock as a FU to the monopoly to social media content platforms. However, it does bring into question how much of an influence they really have given how personal savings have fallen back to 2016 levels . This idea is only valid as long as we don't close under $12.05 on a daily candle.
Max price point I could see it going would be ~$52-$65 given how BBBY had a max mcap of $2.5B after WSB made its move on it (But lets not forget that it was short squeezed). Realistically, I can see it going to $17-$27. Good entries for a long at this point are ~$12, $11.35, and $10.30.
Max low price: 10.00
Max high price: 65.00
Trade:
Entry:12.19
SL:11.22
TP:17, 25, 50, 65
$AMZN (Amazon) Stock - AnalysisIn my opinion, Amazon has completed (or is about to complete) a full market Supercycle: Impulse Wave (I) and Corrective Wave (II).
What I would anticipate would be for Amazon to accumulate during the recession and then emerge out of it with Supercycle Impulse Wave (III).
$GMPR Huge Restaurant Acquis/Military Contracts/Retail ExpanCorporate Update Highlights:
1.Finalize the pre audits, audited financials with M&K CPAS, PLLC to finish the necessary financial statements for uplisting to NASDAQ.
2. Hire fulltime CFO
3. Acquisition of Black Rock Bar & Grill which was voted the #1 Steakhouse in Michigan 3 years in a row!
4. Pizza Fusion deal with US Military. Thier Gourmet Gluten-Free Frozen Pizzas in 150+ grocery stores, in 5 different states, through two food distributors Gia Russa & McAneny Brothers.
In March GMPR was 1 of 22 companies invited to the DeCA Arm Forces Food Service Military Show in Petersburg, VA. The US Military Food Service decision makers attended the show, sampled, loved and approved our Pizza Fusion’s Founders Pie for the US troops in Kuwait.
We have been told we have been approved to feed 36,000 US Troops based in Kuwait for two lunches and one dinner per week and all events and parties.
5. Cousin T’s expansion into retail and introduction of new products; Jose Madrid Salsa into food distributor McAneny Foods; PopsyCakes partnered with $16 million Chocolate company in Pittsburgh.
Gourmet Provisions International signed a distribution partnership with comedian Terrence K. Williams and launched his Gourmet line of Pancake mix under Williams’ custom brand Cousin T’s. in October 2021.
In early 2021 GMPR partnered with Williams to help create and launch a Gourmet line of food products starting with his own personal line of Gourmet Pancake Mix & Syrup all under his custom brand, ‘Cousin T’s’
www.CousinTs.com
www.globenewswire.com
There's no reason for it to be down here this low imo, huge moves should be coming here.
Twitter: Deal is still on, says Musk!!Twitter
Short Term - We look to Buy at 39.16 (stop at 37.32)
They recently gave Elon Musk more information as he requested and deal seems to be still forging ahead. The sequence for trading is higher highs and lows. This is positive for sentiment and the uptrend has potential to return. There is scope for mild selling at the open but losses should be limited. Dip buying offers good risk/reward.
Our profit targets will be 43.86 and 46.00
Resistance: 44.00 / 46.00 / 52.00
Support: 39.00 / 34.00 / 28.50
Please be advised that the information presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Signal Centre’). Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Signal Centre.
USDC hitsThe circulation of USDC has more than doubled since the original deal was announced, reaching $52.7 billion as of the above date.
Jeremy Allaire, Circle’s co-founder and CEO expressed optimism about the new partnership. He was targeting a public listing through the above merger with an SPAC (special purpose acquisition company), which would augment trust and confidence in Circle. He commented:
Circle has made massive strides toward transforming the global economic system through the power of digital currencies and the open internet. This is a critical milestone as we continue our mission to build a more inclusive financial ecosystem. Making this journey with Concord under our new agreement is a strategic accelerator.
Initially, the plan was to conclude the new agreement on December 8, 2022 with the potential to extend to January 31, 2023. Then, the company would be listed on the New York Stock Exchange under the stock ticker symbol ‘CRCL’.
The agreement was approved by the boards of directors of Circle and Concord Acquisition Corp. The latter’s executives also expressed a positive attitude toward the deal. Concord Chairman Bob Diamond said:
We believe our new deal is attractive because it preserves the ability of Concord’s public stakeholders to participate in a transaction with this great company.
Is it the time to buy some Nvidia?As of the last 2 months, there have been some very interesting progressions in NASDAQ:NVDA 's stock. In the beginning of November, they had a drastic price climb (15 percentage points) in the stock due to their announcement of their strong third quarter earnings. Although, a couple of weeks later (the present) their stock has tumbled a considerable 7% and there are many debates on whether the stock shall continue to fall or will have a kickback. Nonetheless, this may present an ideal opportunity to purchase some semi-conductor stocks if it suits your fancy.
For those who have not been following the recent news, Nvidia recently proposed and was acting on an acquisition of ARM a British based semi-conductor company at the hefty price of $40B. The Federal Trade Commission sued Nvidia to have this exchange blocked. Shareholder's were in high hopes for this acquisition as it would benefit Nvidia immensely but the argument that, this would allow them to have an unfair market monopoly has most probably put the "nail in the coffin" for the 'little' business maneuver.
Now the question is, does this price drop make NASDAQ:NVDA quite the attractive purchase for the trader? Personally, I reckon it could be justified based on the trader's frequency of actions. If you plan on holding Nvidia for less than 3 months, you could turn a nifty profit, but if you're looking toward the longer term; you may want to wait for a more considerable price drop as by many investors' standards, it is overpriced.
As usual, other opinions, facts and news are very welcome. Comment away!
TL;DR: Nvidia's price drop as of recent could justify buying for short term trade profits but other wise, 'longer-term' investors may want to wait for a more considerable drop.
Something is cooking here2 key points with huge volume
Do you guys believe Wish is on about to be acquired?
Anything below previous lows is an EXIT from the position for me.
$APYP R/M Into SleepX Could Make it a MASSIVE Runner PT: $1+On Nov 11th the company was successfully redomiciled to Nevada leaving just the last administrative steps towards the completion of the merger in December.
twitter.com
FRANCE Patent No. EP11819507.2 renewed in September
twitter.com
UK Patent No. EP2608717 renewed in September
twitter.com
Israeli Patent No. 224854 renewed in August
twitter.com
SleepX also has a portfolio of FIVE patents some of which are used in Fitbit:
www.sleepxclear.com
Intellectual property
The company’s technology is protected by patents in order to provide a strong IP protection, one of the Company's most important assets. Its technology, applications and products, both in the medical and nonmedical fields, are protected by the laws of the United States and other jurisdictions worldwide. The Company's measurement technology utilizes a technique that measures a range of physical parameters as a function of time to a level of accuracy previously unattainable.
The company's patent portfolio includes:
***SYSTEMS AND METHODS FOR SNORING DETECTION AND PREVENTION***
1. HIGH-SENSITIVITY SENSORS FOR SENSING VARIOUS PHYSIOLOGICAL PHENOMENA, PARTICULARLY USEFUL IN ANTI-SNORING APPARATUS AND METHODS.
2. APPARATUS FOR USE IN CONTROLLING SNORING AND SENSOR UNIT PARTICULARLY USEFUL THEREN.
3. APPARATUS AND METHOD FOR DIAGNOSING SLEEP QUALITY
4. ESTIMATION OF SLEEP QUALITY PARAMETERS FROM WHOLE NIGHT AUDIO ANALYSIS
5. APPARATUS AND METHOD FOR DIGNOSING OBSTRUCTIVE SLEEP APNEA
With distinctive innovative sensor technologies and algorithms, the Company is well-positioned to become a market leader in the snoring and obstructive sleep apnea treatment markets.
twitter.com
twitter.com
The company also signed an agreement with NewsDirect's PR Firm for upcoming press release and marketing capabilities once everything has been finalized and completed.
twitter.com
www.sleepxclear.com
$IFXY 62% Owned by Krisa/Cooley Biggest R/M or Holding CmpyKrisa Management and Carey Cooley own 62% of all Common Shares
twitter.com
www.otcmarkets.com
They have continually said that this will be their biggest merger out of all their shells
twitter.com
twitter.com
In their most recent update they announced that the launch is getting closer and is almost ready. They are also working on two acquisitions already turning $IFXY into possibly a holding company for multiple acquisitions.
twitter.com
"The $IFXY launch is getting closer. @CareyCooley is working hard on a deal to get his preferred COO on board. We are also trying to negotiate deals for our first two acquisitions."
$IGEX Massive DD Huge Potential for a Major Run Personal PT $1+Caren Currier in the wheel house driving this merger
www.otcmarkets.com
Pink Current = unaffected by new SEC/Broker rules everyone is freaking out about. Current before OTCMarkets suggested June30th deadline to ensure survival. This may sound trivial, but it huge!
www.otcmarkets.com
ZERO Liabilities/Debt = see current filings
www.otcmarkets.com
No Dilution for over a year = OTC regularly updated, TA not gagged
www.otcmarkets.com
Small float recently updated on OTCMarkets
Most outstanding shares held by insiders in the company.
Float fairly locked and moves on small volume.
Change of control:
backend.otcmarkets.com
Pending merger and acquisitions acknowledged by company directly in their OTCMarkets profile
"Focus on a merger and some acquisitions" quite possibly lithium related.
Previous to that company hinted:
"Focus on the acquisition and exploration of mineral properties in Nevada"
www.otcmarkets.com
$PUGE New CEO/Attorney/Board Members/Multiple Catalysts PT $1+Multiple Catalysts on the Horizon this one is a true gem of the OTC and could very well end up being one of the farthest moving plays this upcoming season. PT $1+
New CEO Came from a $1.4B Rev hospital
New Attorney CLO who happens to own Glades
3 Brand New Board Members with immense Backgrounds (Humana, Ex Florida Senator, Professor and Ex CEO)
Multiple Acquisitions & Projects in Health, Nano & AI Etc.
In process of closing a $20 Mill Offering
Def Agreement 8K out this week:
www.sec.gov
$TONR New Domain Reg / Upcoming Merger and Twitter Updated PT $1$TONR Management has a Roadmap that will likely take this stock to around a $1 sometime next year given the numerous catalysts to name a few:
1. Debt Cancellation
2. Share Cancellation
3. Reverse Merger
4. OTCQB
Their old twitter and Facebook were removed today and OTCM was updated with the new twitter
twitter.com
twitter.com
A New Domain was also registered today as well:
www.whois.com
Roadmap:
twitter.com
$CYBL Multiple Rev Streams + Possible 525% Rev Increase PT: $1$CYBL has MULTIPLE revenue streams we have yet to even scratch the surface on.
FCS = FUTURE COMBAT SYSTEMS
1. FCS Battle Command
2. FCS SOSCOE (System-of-Systems Common Operating Environment)
3. Telecommunications
www.youtube.com
www.youtube.com
$CYBL from the latest info on the Infrastructure Bill, every state will receive at least $100M for #RuralBroadband and underserved areas even more. With #CyberluxITS
@CyberluxCFBD Group, we're primed and ready to deliver in this area. $45M opportunity they've identified here.
twitter.com
$LEAS Major Pharma Potential with Acquisitions lined up PT .50PHARMIA’s $LEAS goal is to become a leading generics and super-generics company within 5 years. In executing its Plan, PHARMIA will take a three stage approach to the achievement of its goals.
Stage 1
In the initial stage, PHARMIA will launch the company by acquiring MAs in Europe and ANDAs in the United States for generic products that are essential medicines in chronic short supply. PHARMIA will use 3rd parties in Germany to manufacture our oncology products and we will commercialize these “supply challenged” products which generally are older but “mainstay” life-saving medications for the treatment of cancer and infectious diseases, to include the drug shortages caused by the COVID-19 pandemic, where PHARMIA’s team has particular expertise. We will build the drug portfolio and the PHARMIA “brand name” during Stage 1.
Stage 2
In the second stage of PHARMIA’s strategic plan, the company will develop and commercialize a portfolio of novel branded “super-generics” (super-generics are “better than generics” as they have added value and are patented). To achieve this goal, PHARMIA will capitalize on its ownership of the active pharmaceutical ingredients (“API”) acquired in Stage 1, and utilize the scientific and technical development expertise of its team members to reformulate the API of those generics into patented formulations. The goal is to create novel, patentable formulations with novel and improved characteristics (such as extended release, dissolvable films and implants, multiple drug combinations in one pill, etc.) that are more patient friendly, and more easily administered. The development of a portfolio of “super-generics” during Stage 2 will be a major revenue driver going forward. This “value add” will enhance patient compliance and therapeutic outcomes, differentiating PHARMIA pipeline from the competition. Also during Stage 2, the acquisition and development of biologic medicines (“antibodies”) targeting oncology will have begun, with the company already licensing three antibodies that have been fully developed and are on the market in several countries. It is PHARMIA objective to start and complete Phase 3 clinical trials of each “biosimilar” antibody targeting breast cancer, colorectal cancers, brain cancers, and several other solid tumors. Stage 2 is an important growth phase for the company.
Stage 3
In the third stage of growth, PHARMIA will focus its attention on acquiring its own manufacturing facilities in the USA for the production of Active Pharmaceutical Ingredients (APIs) and final, formulated Drug Product dosage forms. This will enable the company to totally control the whole supply chain process and also expand its portfolio of products that are, or are expected to be, in chronic short supply or suffering from ongoing quality issues when supplied from outside the USA or Europe. With its own manufacturing infrastructure in place, PHARMIA will have the capability to meet supply demand by expeditiously switching manufacturing from one product to another in the same facility with only minor process changes required. The company will expand its sterile injectable drug manufacturing capabilities and its solid dosage form (super-generics) capacity during Stage 3.
Starting with high quality but low-cost, affordable generic drugs treating deadly diseases, the second phase of grow is by employing pharmaceutical drug delivery technologies to enhance and improve the generic drug incorporated in the drug formulation as a “super-generic”. Our super-generics employ a technology called “3-D screen printing” of drugs with extended release properties and will provide a sustained drug level within the “therapeutic window” for once-a-day dosing. A single pill containing three or four medicines that can be taken once-a-day, and this approach provides the patient a lower “pill burden” and this will result in better compliance in taking the medicine and overall improved care of the patient.
The company is working on 3-D screen-printed medicines with novel dissolution and release characteristics. 3-D screen-printing technology opens up new, flexible and versatile options for the pharmaceutical industry in the manufacturing process of their products. Thousands or even millions of medical doses can be manufactured per machine per year. The 3-D screen-printing process allows for many different kinds of shapes, sizes and compositions.
We are committed to maintaining our entire business operations including the 3-D screen printing commercial manufacturing in America, Canada, and/or Europe (Ireland and Germany), and we will continue to build strong, lasting relationships with European and our Nation’s largest pharmacy chains, wholesalers, and distributors.
Essential Medicines – Affordable Prices
investorshub.advfn.com
Dr. Joseph Sinkule
Co-Founder, Chief Executive Officer (CEO) and Director
www.pharmia-inc.com
Strategic Asset Leasing Inc. Announces Cryptocurrency Launch Press Release | 10/06/2020
Strategic Asset Leasing Inc. Announces Cryptocurrency Development Press Release | 10/02/2020
Strategic Asset Leasing Inc. Enters Into MOU Press Release | 09/30/2020
Strategic Asset Leasing Inc. Announces New Subsidiary Press Release | 09/29/2020
Strategic Asset Leasing Inc. Enters Into Additional LOI Press Release | 09/25/2020
Strategic Asset Leasing Inc. Joins Open Source Projects Press Release | 09/24/2020
$CGAC Caren Currier Shell Awaiting Upcoming Merger PT - .50 DD So Far:
No dilution since 10/28
2.28B OS
13-G filed. Someone bought 92.5M shares on 9/23/2021
Someone obviously knows something.
Caren Currier is known as one of the top merger consultants
As you can see, we are expecting OS between 2B to 2.5B based on the conversion rate with 50% discount from 52 week low on the Loan agreement. As per this email Mr. Powell can drop a news anytime:
twitter.com
$MWWC Reduced A/S by 70% Acquires Major Crypto Platform PT .10+"Excited to FINALLY be able to reveal what $MWWC has been up to! We've fully acquired a #CryptoMining platform, and will be ready for test groups within WEEKS! We'll keep you posted on how to sign up. First of many wins!"
"Marketing Worldwide $MWWC Update - Commercial mining operation fully active and integrated with speeds clocking 2.18 p/h"
twitter.com
www.accesswire.com
November 3, 2021 / Marketing Worldwide Corporation, (OTC PINK:MWWC), "the Company," launches a 3-part plan to expand operations.
Part I: Commercial Mining Operation
Marketing Worldwide Corporation has officially contracted its first medium scale crypto-currency mining operation, which will mine Bitcoin through the Minosis platform pool. This Commercial operation consists of Bitmain Antminer SJ19 Pro units that operate at 104T/H of mining capacity with approximately 3,250 kw/h of power consumed per unit.
At the time of this release the price of Bitcoin was $63,007.48 per #BTC
Utilizing the www.cryptocompare.com calculator feature this is the information that can be derived from profit potentials of the Commercial Mining Operation on a PER UNIT BASIS.
**Per the illustration above, conservative profit projections are $20,466.00 or (.33) of #BTC generated per month.
Marketing Worldwide has taken possession of an existing warehouse storefront and is evaluating its use for the 15,000 Sq Ft commercial facility; the department store is already outfitted with 2400 Amp power and 12' high ceilings. "If Marketing Worldwide wants to rent out increased hash rate on the Minosis platform, then it only makes sense for us to dip our toes into the commercial crypto mining industry and stake our claim. This facility could easily accommodate up to Sixty (60) Antiminer SJ19 Pro(s) and Three Hundred (300) Mini-Doge/LTC Miners," explained CEO Jason Schlenk.
Additional information regarding the new commercial location will be announced via social media from the official twitter account @MWWCOfficial in the near future.
Part II: Non-Dilutive Line of Credit
Marketing Worldwide has procured a non-dilutive line of credit up to $1.5 Million USD which can be utilized for marketing, further development of the Minosis platform and the acquisition of additional ASIC Miners to establish MWWC as a Commercial Mining Operation. The line of credit carries an interest rate of 5% APR and is available on request.
MWWC CEO Jason Schlenk states, "As the Company grows into its new endeavors, we can rest easy knowing that we won't have any capital restrictions preventing us from achieving our short-term goals, and the shareholders won't have to worry about toxic financing or convertible debts."
Part III: Minosis Support and Integration:
The Company launched the testing version of the Minosis mining platform just over a week ago, allowing random registered users access into the dashboard to test the Minosis Agent and the mining process, as well as, the functionality of the portal. To date, the company has received some extremely valuable input to fix memory leakage with the majority of user feedback being positive. As the applications continue to develop, the Company will incorporate in the Minosis Teams and Minosis Pool functions, which should appear in mid-stage testing in late November or early December.
"One of the fundamental keys to the Minosis platform is the continued development of the Minosis Teams and Minosis Pool features. These two attributes are what make Minosis unique, and the proprietary technology brings exponential value to our business model", said CEO Jason Schlenk.
July 7, 2021 / Marketing Worldwide Corporation, (OTC PINK:MWWC), 'the Company', is pleased to announce three major corporate updates to the shareholders.
Marketing Worldwide recently hosted a majority shareholder meeting where the new management and leadership team was elected. At the same time the official transfer agent was changed from 'Continental Stock Transfer' to ‘Issuer Direct.' The Company is pleased to report that all associated fees for this action have been paid in full and ‘Issuer Direct' has been working hard for the benefit of the Company.
Additionally, the Company approved moving the domestication of Marketing Worldwide to the State of Wyoming with the intentions of dissolving the Delaware entity. Future State filings, amendments, and documentation should appear in those respective States as they continue to be processed under the direction of corporate legal counsel.
Lastly, an internal audit and review of the share structure has taken place over the last week. The Company will be cancelling 7.4 billion shares from the authorized share count during the Wyoming relocation per the approved ‘Board Resolution MW07.06.2021'. The new authorized share total will be 3.5 billion shares of common stock, reduced from the former 10.9 billion shares.
Jason Schlenk, the newly appointed CEO of Marketing Worldwide said, "I am thrilled to see how far we have come in a short period of time, and that we are efficiently executing to achieve a number of short-term milestones." Mr. Schlenk continued, "I have already submitted my application to OTC Markets for subscription services over a week ago, and look forward to seeing any updates or requests for more information as they deem appropriate. Obviously, our goal of getting back to a pink current standing is of priority importance, and I thank everyone for their continued support."
$NOHO Caren Currier Potential R/M with Massive Potential PT: .10A $NOHO STORY - THE PROLOGUE -
What follows is the story of $NOHO.
It’s long, but the DD, less daunting!
DD with links, photos and data included here: investorshub.advfn.com
Now let's get into it!
What transpires below has been collected by a collective of sleuth DD professionals on Twitter. Shout out to @PaulSEO403 for putting it all together.
The CEO has been amazing. If management stays true, we will report all the way through!
And with all that out of the way, lets begin!
INTRO
A NEW LIFE
While the company engaged in various businesses prior to 2018, it has been inactive from 2018 to 2021.
Feel free to check their latest 10Q for past history, but for this purpose, I will cut the fat:
CHAPTER 1
CEO - MICHAEL GELMON
Mr. Gelmon Co-founded & was Director of Domino’s Pizza of Canada! He also founded Gelmon Corporation, developing over $300 Million in commercial real estate! A lawyer by trade, he has consulted many companies over the years!
CHAPTER 2
REINSTATEMENT
While I believe Mr. Gelmon has been preparing for the $NOHO revival for quite some time, it officially became reinstated with the State of Florida on July 8, 2021.
CHAPTER 3
NAME CHANGE
$NOHO is no longer Dragon Life Science Holdings Group.
A Name Change Amendment with the State of Florida was filed on August 10, 2021.
$NOHO is now Novation Holdings!
CHAPTER 3A - NOTE
PAST NAME CONFUSION
If you see Dragon Life Science references around, it’s because the latest 10Q was executed on August 4, 2021 (Still as Dragon Life).
The name change to Novation Holdings occurred 6 days later:
CHAPTER 4
CAREN CURRIER
If you trade the OTC, you know that Caren Currier plays are highly sought after.
If you’re wondering if she is still involved, here is Mr. Gelmon’s response to my inquiry.
Currier is on board!
CHAPTER 5
FILINGS
1. ALL filings dropped in one day! This tells me Gelmon & Currier were prepared FOR A WHILE!
2. Filings dropped 8/11 - THE DAY AFTER Name Change Amendment executed 08/10. Once again, FORWARD LOOKING!
CHAPTER 5A
FILINGS RESULTS
Efficient and proper filings with help of Caren Currier removed all doubt ahead of new SEC regulations. Yield 8/12, the day after filings dropped and now, of course, PINK!
CHAPTER 6
BIRTH OF @NovationNOHO
In August, a Twitter account was started for $NOHO.
They do not give frequent updates, YET!, but soon, we should see them posting more frequently! Check their latest updates:
CHAPTER 7
WEBSITE
To complement the Twitter account, a clean, modern, and clear website was created take a look!:
novationholdings.com
CHAPTER 8
CLEANING UP PAST
$NOHO is now a “multi-strategy holdings company.”
This requires a CLEAN shell. $NOHO had convertible debt. Part of this (1.5B shares) was completed between March-May 2021.
AGAIN! CEO HAS BEEN PREPARING FOR A LONG TIME!
CHAPTER 8A
MORE CLEANING
Last slide shows O/S just under 10B as of 5/31/21. Recently, more debt was converted to same entities.
This is business. Loans must be repaid. Its ethical and necessary. Better now than later. Remember $ILUS?
CHAPTER 8B
LAST OVERHANG
Last loan outstanding is to the CEO himself.
CEO investing his own funds and not taking pay? Still, he writes, “No plans to take the note any time soon.”
I asked him this tough question. Can you ask for a better response?
CHAPTER 8C
ABSORB THAT
Did you read his response?
“Not worried about overhand.”
“It will be a blip on the radar.”
“As an Insider I cannot sell any of that or convert any of that as long as I’m an affiliate with the company.”
CHAPTER 9
AUDIT & UPLIST
Two week ago, $NOHO released a PR announcing “Engagement of PCAOB Auditor/Accounting Firm in Preparation for Up-listing to OTCQB.”
PPS Requirement of an Up-listment to OTCQB is .01+ for 30 days
CHAPTER 10
CURRENT
This brings us to now:
- AUDITING FINANCIALS
- PREPARING FOR UPLIST
- CAREN CURRIER ON AUDIT
- PCAOB AUDITOR RETAINED
- CLEAN SHELL
- MULTI-STRATEGY HOLDING COMPANY READY TO “INCREASE SHAREHOLDER VALUE.”
CHAPTER 11
WHAT’S AHEAD?
Quotes from the CEO:
“Obviously, we have exciting plans or we would not be spending time and money getting this company ready.”
“We will certainly be on Twitter when we have news to report.”
CHAPTER 11A:
ACQUISITIONS
When I asked for clarification on his personal history, he shared, but also stated:
“The real story is about the acquisitions that we will be making.”
That’s plural! Remember: “Multi-Strategy Holdings Company!”
CHAPTER 12
PUTTING IT TOGETHER
When the Audits & Uplist PR dropped, I knew this story was changing drastically.
CEO conviction is shared via E-Mail. Not Twitter; A lawyer, Consultant, and Founder, working with people like Caren Currier.
I’m in!
IN CONCLUSION
As long as @NovationNOHO stays consistent, continues to communicate impeccably, & executes it’s strategy, we will continue to report!
There is risk with any trade. Obviously, Do your own DD. Trade your trade!
LAST WORD
WE ARE EARLY.
This is one of the few pink current tickers still left under .0020 with a very good story and working details + potential catalysts.
This fall will potentially create many millionaires, will you be one of them? Will this company come ahead of the pack and do that?
I'll be here to watch. Together Fam.